Skip to content

免疫诺姆

US · IMNM #2671 按市值排名 上市于 2020
16.47 -0.93 -5.34%
实时 - 追踪5344个代码 - 心跳于247秒前 · 2026-10-16 20:01

估值 各估值倍数与自身5年区间的对比

市净率 4.34 处于历史正常水平 第66百分位
5年平均 14.07 · 在Biotechnology中排名第362/514
市盈率 -7.63 低于历史水平 第17百分位
5年平均 -3.86 · 前瞻 -7.38
市销率 567.53 高于历史水平 第94百分位
5年平均 113.45 · 前瞻 323.73 · 在Biotechnology中排名第335/388

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
免疫诺姆 (IMNM) 1.94B -6.51 3.70 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值22.58 经济护城河None 不确定性Very High

当前股价低于晨星合理价值估算37.1%。

合理价值

Immunome Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% discount to our quantitative fair value estimate of $22.58 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet bolsters our estimated valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 15.1, which sits in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 0.8, a core component of valuation, sits in the bottom 20% compared with peers globally. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:01:17 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

免疫诺姆 讨论区 0 条评论

发表评论